journal
https://read.qxmd.com/read/38307101/design-and-implementation-of-a-humanitarian-cancer-care-programme-for-ukrainian-refugees-in-moldova-and-romania
#21
JOURNAL ARTICLE
Horia Vulpe, Artiom Minzatean, Irena Tocino, Ruslan Baltaga, Gabriel Kacso, Claudia Oprea, Veronica Ciobanu, Sergiu Brenister, Ciprian Tomuleasa, Gabriel Ricu, Rodica Mindruta-Stratan, Catalin Danaila, Dragos Iancu, Ludmila Circiumari, Cristian Teglas, Lars Lonnback, Violina Nazaria, Ursula Wagner, Eugenia Ciubotaru, Nicoleta Minzatean, Ciprian Jitaru, Stanislav Polozov, Inessa Matiushenko, Anna Uzlova, Richard Sullivan, Stefania Magidson
No abstract text is available yet for this article.
January 30, 2024: Lancet Oncology
https://read.qxmd.com/read/38281492/substance-use-disorders-among-cancer-survivors
#22
JOURNAL ARTICLE
Sharmila Devi
No abstract text is available yet for this article.
January 25, 2024: Lancet Oncology
https://read.qxmd.com/read/38224701/low-dose-versus-standard-dose-olanzapine-with-triple-antiemetic-therapy-for-prevention-of-highly-emetogenic-chemotherapy-induced-nausea-and-vomiting-in-patients-with-solid-tumours-a-single-centre-open-label-non-inferiority-randomised-controlled-phase-3-trial
#23
JOURNAL ARTICLE
Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, Sravan Kumar, Anbarasan Sekar, Priyanka Patil, Altaf Siddiqui, Srikanth Anne, Akash Pawar, Sujay Srinivas, Prabhat Bhargava, Seema Gulia, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta
BACKGROUND: Olanzapine is an effective antiemetic agent but it results in substantial daytime somnolence when administered at the standard dose. Our aim was to compare the efficacy of low-dose versus standard-dose olanzapine after highly emetogenic chemotherapy in patients with solid tumours. METHODS: This was a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial done in a tertiary care referral centre in India (Tata Memorial Centre, Homi Bhabha National Institute, Mumbai)...
January 12, 2024: Lancet Oncology
https://read.qxmd.com/read/38211607/developing-therapies-for-triple-negative-breast-cancer-subtypes
#24
JOURNAL ARTICLE
Alicia Okines, Nicholas Turner
No abstract text is available yet for this article.
January 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38190836/nigerian-competition-watchdog-fines-british-american-tobacco
#25
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
January 5, 2024: Lancet Oncology
https://read.qxmd.com/read/38142703/sub-saharan-africa-s-harmonised-cancer-guidelines
#26
JOURNAL ARTICLE
Munyaradzi Makoni
No abstract text is available yet for this article.
December 21, 2023: Lancet Oncology
https://read.qxmd.com/read/38142701/expression-of-concern-alpelisib-plus-fulvestrant-in-pik3ca-mutated-hormone-receptor-positive-advanced-breast-cancer-after-a-cdk4-6-inhibitor-bylieve-one-cohort-of-a-phase-2-multicentre-open-label-non-comparative-study
#27
JOURNAL ARTICLE
https://read.qxmd.com/read/38142700/accelerating-neoadjuvant-chemotherapy-for-muscle-invasive-bladder-cancer
#28
JOURNAL ARTICLE
Laura S Mertens, Michiel S van der Heijden
No abstract text is available yet for this article.
December 21, 2023: Lancet Oncology
https://read.qxmd.com/read/38142699/high-health-expenses-in-the-who-western-pacific-region
#29
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
December 21, 2023: Lancet Oncology
https://read.qxmd.com/read/38423067/optimal-imaging-before-local-therapy-of-colorectal-liver-metastases
#30
LETTER
Antony Haddad, Mateo Lendoire, Iwan Paolucci, HyunSeon Christine Kang, Jean-Nicolas Vauthey
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423066/uncovering-causal-clues-in-the-development-of-second-primary-cancers-authors-reply
#31
LETTER
Trille Kristina Kjaer, Christoffer Johansen, Susanne Oksbjerg Dalton
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423065/uncovering-causal-clues-in-the-development-of-second-primary-cancers
#32
LETTER
Huan Yi, Jianguang Ji
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423064/calla-trial-immunotherapy-in-locally-advanced-cervical-cancer-authors-reply
#33
LETTER
Bradley J Monk, Jyoti Mayadev
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423063/calla-trial-immunotherapy-in-locally-advanced-cervical-cancer
#34
LETTER
Xi Yang, Yuanyuan Zhang, Shuangzheng Jia, Jusheng An, Manni Huang
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423062/calla-trial-immunotherapy-in-locally-advanced-cervical-cancer
#35
LETTER
Fadila Kouhen, Mohammed Sqali Houssaini
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423061/accurately-addressing-double-arm-zero-events-studies-in-meta-analyses-authors-reply
#36
LETTER
Yu Fujiwara, Nobuyuki Horita, Abdul Rafeh Naqash
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423060/accurately-addressing-double-arm-zero-events-studies-in-meta-analyses
#37
LETTER
Qi Zhou, Yaolong Chen
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423059/paraneoplastic-dermatoses-in-a-patient-with-gastric-adenocarcinoma-cutaneous-clues-to-internal-malignancy
#38
JOURNAL ARTICLE
Tai-Li Chen, Tsung-Hsien Chang, Cheng-Yuan Li
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423058/lessons-learned-from-postmarketing-withdrawals-of-expedited-approvals-for-oncology-drug-indications
#39
REVIEW
Simone N Koole, Atse H Huisman, Lonneke Timmers, Hans M Westgeest, Edwin van Breugel, Gabe S Sonke, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
In the past decade, there have been a record number of oncology therapy approvals by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Besides the EMA's conditional marketing authorisation programme and the FDA's Accelerated Approval Program, we observe a tendency towards fast approval for exploratory studies with non-randomised, uncontrolled designs and surrogate endpoints. This issue raises concerns about the robustness and effectiveness of accepted treatments, leaving patients and health-care professionals in a state of uncertainty...
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423057/non-surgical-ablation-for-breast-cancer-an-emerging-therapeutic-option
#40
REVIEW
Masakazu Toi, Takayuki Kinoshita, John R Benson, Ismail Jatoi, Masako Kataoka, Wonshik Han, Chikako Yamauchi, Takashi Inamoto, Masahiro Takada
Non-surgical ablation is emerging as an alternative local therapy option for patients with early-stage breast cancer and encompasses two main types of percutaneous therapeutic procedures: radiofrequency ablation and cryoablation. Both techniques involve obliteration of a spherical lesion and feasibility studies have shown that complete tumour ablation is achievable with good or excellent cosmetic results. Although few clinical studies have directly compared non-surgical ablation with conventional surgical resection, observational studies indicate that clinical outcomes are favourable with acceptable rates of local control and no detriment to long-term survival...
March 2024: Lancet Oncology
journal
journal
20189
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.